Abstract: In this continuing efforts toward the development of disease modifying treatments for inflammatory diseases, we are targeting the development of novel p38 Mitogen-activated Protein (MAP) kinase inhibitors. In present study, we reported molecular docking studies of substituted pyrazolone derivatives with cytokine synthesis inhibitors.